Department of Investigational Cancer Therapeutics, 1400 Holcombe Blvd., Unit 455, Site 201 — Houston, Texas

Department of Investigational Cancer Therapeutics, 1400 Holcombe Blvd., Unit 455, Site 201 is a clinical research site located in Houston, Texas, United States 77030.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Department of Investigational Cancer Therapeutics, 1400 Holcombe Blvd., Unit 455, Site 201 has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Solid Tumors.

Sponsors: EDDC (Experimental Drug Development Centre), A*STAR Research Entities.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Department of Investigational Cancer Therapeutics, 1400 Holcombe Blvd., Unit 455, Site 201?

Department of Investigational Cancer Therapeutics, 1400 Holcombe Blvd., Unit 455, Site 201 has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Department of Investigational Cancer Therapeutics, 1400 Holcombe Blvd., Unit 455, Site 201 conducted?

Department of Investigational Cancer Therapeutics, 1400 Holcombe Blvd., Unit 455, Site 201 has 1 clinical trials on record, with 1 currently active. Their work covers Solid Tumors.

Is Department of Investigational Cancer Therapeutics, 1400 Holcombe Blvd., Unit 455, Site 201 accredited by Crixeo Health?

Department of Investigational Cancer Therapeutics, 1400 Holcombe Blvd., Unit 455, Site 201 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Department of Investigational Cancer Therapeutics, 1400 Holcombe Blvd., Unit 455, Site 201?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.